Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Emerging agents like Tirzepatide, which activates both GLP-1 and GIP receptors, and Orforglipron, a nonpeptide oral GLP-1 agonist in phase 2 trials, further expand the therapeutic potential of this class (23)(24)
Recent analyses comparing GLP-1 medications to bariatric surgery have found surgery to offer better value in certain populations, despite its invasive nature
While effective for blood sugar control and appetite suppression, the drug has been linked to serious side effects that were allegedly not adequately disclosed to patients or healthcare providers
PLOS Medicine 4(8): e264
US$ 21.76
US$ 29.73
US$ 20.38
